USPTO Art Unit 1611 Prosecution Statistics

Art Unit Information

Art Unit: 1611
Group: 1610
Tech Center: 1600
Total Cases: 9,974
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19060293URSOLIC ACID MORPHOLINE SALTFebruary 2025June 2025Allow310YesNo
19022909SLEEP-IMPROVING COMPOSITIONS AND METHODS OF USEJanuary 2025March 2025Allow200YesNo
19022531LEVODOPA DOSING REGIMENJanuary 2025April 2025Allow300YesNo
19021929LEVODOPA DOSING REGIMENJanuary 2025June 2025Allow510NoNo
19022122LEVODOPA DOSING REGIMENJanuary 2025April 2025Allow310NoNo
19021696LEVODOPA DOSING REGIMENJanuary 2025June 2025Allow510NoNo
18944456AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATIONNovember 2024June 2025Allow710YesNo
18934978PHARMACEUTICAL COMPOSITIONSNovember 2024April 2025Allow610YesNo
18915144READY-TO-USE SODIUM PHOSPHATES INJECTIONOctober 2024February 2025Allow410YesNo
18910781URSOLIC ACID MORPHOLINE AND DIETHANOLAMINE SALTSOctober 2024November 2024Allow100YesNo
18904951Constrained Ionizable Cationic Lipids and Lipid NanoparticlesOctober 2024May 2025Allow801NoNo
18897019Pathogenic Affinity Pathway of Infectious or Parasitic Organisms for Nanogram and Picogram Dosimetry Prophylaxis or CureSeptember 2024December 2024Allow300YesNo
18894811THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE TO TREAT MAJOR DEPRESSIVE DISORDERSeptember 2024March 2025Allow610NoNo
18823575LEVODOPA DOSING REGIMENSeptember 2024April 2025Allow710NoNo
18823153LEVODOPA DOSING REGIMENSeptember 2024December 2024Allow310NoNo
18817743LEVODOPA DOSING REGIMENAugust 2024February 2025Allow610YesNo
18802458LEVODOPA DOSING REGIMENAugust 2024February 2025Allow610YesNo
18802151LEVODOPA DOSING REGIMENAugust 2024April 2025Allow820YesNo
18785092IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONEJuly 2024September 2024Allow200YesNo
18785063IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONEJuly 2024September 2024Allow200YesNo
18730659SINGLE-DOSE COSMETIC PRODUCT AND PROCESS OF MANUFACTURING THEREOFJuly 2024February 2025Allow700YesNo
18773898Transdermal Delivery of TetrahydrocannabinolJuly 2024December 2024Allow500YesNo
18759349VIGABATRIN LIQUID PHARMACEUTICAL COMPOSITIONJune 2024March 2025Allow910YesNo
18739339PUERARIA LOBATA NANO-SILVER COMPOSITE HYDROSOL, PREPARATION METHOD AND APPLICATION THEREOFJune 2024November 2024Allow510NoNo
18731605LEVODOPA DOSAGE FORMJune 2024January 2025Abandon810NoNo
18670599METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024March 2025Abandon1010NoNo
18667826READY-TO-USE SODIUM PHOSPHATES INJECTIONMay 2024July 2024Allow200YesNo
18665149SLEEP-IMPROVING COMPOSITIONS AND METHODS OF USEMay 2024December 2024Allow710YesNo
18708606LIQUID DRESSING FOR PROMOTING WOUND HEALINGMay 2024April 2025Allow1110YesNo
18653070METHODS FOR SHRINKING PITUITARY TUMORSMay 2024March 2025Allow1010YesNo
18652849NOVEL POTASSIUM CHANNEL INHIBITORSMay 2024April 2025Allow1201YesNo
18649759NICOTINE TABLETApril 2024June 2025Allow1301NoNo
18645654DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSApril 2024April 2025Allow1110NoNo
18643713PARENTERAL NUTRITION CONTAINING TRACE ELEMENTSApril 2024March 2025Abandon1111NoNo
18640949MICRONIZED EGGSHELL MEMBRANE PARTICLES AND THE USE THEREOF TO PROMOTE THE HEALING OF WOUNDSApril 2024April 2025Allow1210YesNo
18639748COMPOSITION COMPRISING OIL PALM PHENOLICS FOR USE IN THE TREATMENT AND PREVENTION OF COLON DISEASES AND FOR PROMOTING AND MAINTAINING GUT AND GENERAL HEALTHApril 2024March 2025Allow1110YesNo
18635375PYRAZINO[1',2':1,5]PYRAZOLO[4,3-B][1,6]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORSApril 2024July 2024Allow300YesNo
18634040LEVODOPA DOSING REGIMENApril 2024August 2024Allow410NoNo
18628073HIGHLY CRYSTALLINE ALPHA-1,3-GLUCANApril 2024February 2025Allow1010NoNo
18627020SHEET-SHAPED MEMBERApril 2024June 2025Abandon1510NoNo
18615512COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENTMarch 2024September 2024Allow610YesNo
18613281PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASEMarch 2024July 2024Allow400YesNo
18606860THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONSMarch 2024March 2025Allow1220NoNo
18594338Blarcamesine co-crystals for the manufacture of pharmaceutical dosage formMarch 2024April 2025Allow1401YesNo
18588191QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASEFebruary 2024June 2024Allow400YesNo
18589336Compositions, Kits, Methods and Uses for Cleaning, Disinfecting, Sterilizing and/or TreatingFebruary 2024March 2025Allow1320NoNo
18441957ENTERIC TABLET CONTAINING DIMETHYL FUMARATEFebruary 2024May 2025Abandon1510NoNo
18441673METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS VIA ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINFebruary 2024February 2025Allow1210YesNo
18441132MICROENCAPSULATED HERBICIDESFebruary 2024November 2024Allow900YesNo
18438675Compositions and Methods for Treating CNS DisordersFebruary 2024December 2024Allow1010YesNo
184379034,5-BIS(4-CHLOROPHENYL)-1-HEXYL-2-(3,4-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024April 2024Allow200YesNo
18436480DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSFebruary 2024December 2024Allow1010NoNo
18436682DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOFFebruary 2024November 2024Allow910NoNo
18431234DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSFebruary 2024December 2024Allow1010NoNo
184313716'-(2-BROMOPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUNDFebruary 2024June 2024Allow500YesNo
18430224HERBICIDAL COMPOSITIONS FOR ANIMAL GRAZELANDS AND METHODS FOR APPLYING THE SAMEFebruary 2024March 2025Allow1410YesNo
18426972AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATIONJanuary 2024August 2024Allow610YesNo
18416289PHARMACEUTICAL DOSAGE FORMSJanuary 2024March 2025Abandon1410NoNo
18414767ETHYL {[N'-(3-CHLOROPHENYL)-N-(2,4-DICHLOROBENZOYL) CARBAMIMIDOYL]SULFANYL}ACETATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024August 2024Allow710YesNo
18414749ETHYL {[N'-(3-CHLOROPHENYL)-N-(2,4-DICHLOROBENZOYL) CARBAMIMIDOYL]SULFANYL}ACETATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024September 2024Allow810YesNo
18413304Diphenyl Tablets and Methods of Preparing the SameJanuary 2024March 2025Abandon1410NoNo
18413352NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERSJanuary 2024March 2025Allow1401YesNo
18405189NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASSJanuary 2024June 2025Abandon1810NoNo
18405634HYDROGELS AS RHEOLOGY MODIFIERS AND METHODS OF MAKING THE SAMEJanuary 2024November 2024Allow1110NoNo
18404037USP9X InhibitorsJanuary 2024July 2024Allow600YesNo
18404706THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDEJanuary 2024July 2024Allow710YesNo
184034062-OXO-2-({2-[(PHENYLCARBAMOYL)OXY]ETHYL}AMINO)ETHYL PHENYLCARBAMATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024May 2024Allow500YesNo
18392666NEW PHARMACEUTICAL COMPOSITIONSDecember 2023October 2024Allow1020YesNo
18392602NEW PHARMACEUTICAL COMPOSITIONSDecember 2023October 2024Allow1020YesNo
18542993COSMETIC COMPOSITIONS AND METHODS OF USEDecember 2023September 2024Allow900YesNo
18541832INTRAOPERATIVE TOPICALLY-APPLIED NON-IMPLANTABLE RAPID RELEASE PATCHDecember 2023February 2025Allow1420YesNo
18542159PYRAZINO[1',2':1,5]PYRAZOLO[4,3-B][1,6]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORSDecember 2023March 2024Allow300YesNo
18538903IMPLANT WITH FILLABLE RESERVOIRDecember 2023April 2025Allow1610YesNo
18535139DEVICES, KITS AND METHODS FOR REDUCING AND/OR PREVENTING INTRA-ABDOMINAL ADHESIONSDecember 2023February 2025Allow1520YesNo
18530815PHARMACEUTICAL COMPOSITIONS OF MIFEPRISTONEDecember 2023August 2024Allow810YesNo
18528173PEROXYCARBOXYLIC ACID BASED SANITIZING RINSE ADDITIVES FOR USE IN WARE WASHINGDecember 2023February 2025Allow1501YesNo
18527967BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOFDecember 2023May 2025Abandon1701NoNo
18526914NOVEL WOUND DRESSING BASED ON CELLULOSE ACETATE FILMS CONTAINING BINARY METAL OXIDE NANOHYBRIDSDecember 2023May 2025Abandon1730NoNo
18524381GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOFNovember 2023July 2024Allow811YesNo
18524738LIQUISOFT CAPSULESNovember 2023January 2025Allow1410YesNo
185097422-(1-(2-HYDROXYPROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDINE AS AN ANTICANCER COMPOUNDNovember 2023January 2024Allow200YesNo
18388898ORAL SOLID TABLET COMPRISING BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFORNovember 2023September 2024Allow1010YesNo
183881034,5-BIS(4-CHLOROPHENYL)-1-HEXYL-2-(3,4-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDNovember 2023January 2024Allow200YesNo
185042894,5-BIS(4-CHLOROPHENYL)-1-HEXYL-2-(3-HYDROXY-4-METHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow411YesNo
18502986HERBICIDAL COMPOSITIONS FOR ANIMAL GRAZELANDS AND METHODS FOR APPLYING THE SAMENovember 2023March 2025Allow1610YesNo
18386686HERBICIDAL MIXTURES COMPRISING L-GLUFOSINATE AND THEIR USE IN SOYBEAN CULTURESNovember 2023December 2024Allow1310NoNo
183865496'-(2-BROMOPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUNDNovember 2023January 2024Allow200YesNo
183859896'-(3-BROMOPHENYL)-2'-METHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUNDNovember 2023January 2024Allow300YesNo
184989896'-(4-BROMOPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANTOctober 2023January 2024Allow200YesNo
18384489NEEM FOR TREATMENT OF RLSOctober 2023May 2024Allow700YesNo
18384042PREPARATION METHOD FOR MODIFIED NANO-ZINC OXIDE POWDEROctober 2023April 2024Allow510NoNo
184930171-Methyl-4-[(4-Phenylphenyl)Sulfonylmethyl]Cyclohexyanol And 1-Methyl-4-[[4-(2-Pyridyl)Phenyl]Sulfonylmethyl]Cyclohexanol Compounds and Their Therapeutic UseOctober 2023December 2024Allow1301NoNo
18491200Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair CellsOctober 2023February 2025Abandon1610NoNo
18489631TOPICAL DRUG DELIVERY DEVICES AND METHODS OF USEOctober 2023June 2024Allow811YesNo
18487486Compositions Having Improved Bioavailability of TherapeuticsOctober 2023December 2024Allow1421YesNo
18380054SUSTAINED RELEASE FORMULATIONS OF DYSOXYLUM BINEFACTERUMOctober 2023September 2024Allow1101YesNo
18379505BALLOON CATHETERS FOR BODY LUMENSOctober 2023August 2024Allow1110NoNo
18379190DERMAL FILLERS AND APPLICATIONS THEREOFOctober 2023May 2024Allow700YesNo
18485086USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMAOctober 2023September 2024Abandon1110NoNo
18485082USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMAOctober 2023August 2024Abandon1010NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1611.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
428
Examiner Affirmed
324
(75.7%)
Examiner Reversed
104
(24.3%)
Reversal Percentile
13.4%
Lower than average

What This Means

With a 24.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1550
Allowed After Appeal Filing
246
(15.9%)
Not Allowed After Appeal Filing
1304
(84.1%)
Filing Benefit Percentile
1.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1611 - Prosecution Statistics Summary

Executive Summary

Art Unit 1611 is part of Group 1610 in Technology Center 1600. This art unit has examined 9,974 patent applications in our dataset, with an overall allowance rate of 41.5%. Applications typically reach final disposition in approximately 36 months.

Comparative Analysis

Art Unit 1611's allowance rate of 41.5% places it in the 3% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1611 receive an average of 2.43 office actions before reaching final disposition (in the 90% percentile). The median prosecution time is 36 months (in the 15% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.